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Abstract
Introduction
Helminth infection may affect vaccine immunogenicity and efficacy. Adolescents, a target
population for tuberculosis booster vaccines, often have a high helminth burden. We investi-
gated effects of Schistosoma mansoni (Sm) on the immunogenicity and safety of MVA85A,
a model candidate tuberculosis vaccine, in BCG-vaccinated Ugandan adolescents.
Methods
In this phase II open label trial we enrolled 36 healthy, previously BCG-vaccinated adoles-
cents, 18 with no helminth infection detected, 18 with Sm only. The primary outcome was
immunogenicity measured by Ag85A-specific interferon gamma ELISpot assay. Tuberculo-
sis and schistosome-specific responses were also assessed by whole-blood stimulation
and multiplex cytokine assay, and by antibody ELISAs.
Results
Ag85A-specific cellular responses increased significantly following immunisation but with no
differences between the two groups. Sm infection was associated with higher pre-immunisa-
tion Ag85A-specific IgG4 but with no change in antibody levels following immunisation.
There were no serious adverse events. Most reactogenicity events were of mild or moderate
severity and resolved quickly.
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Conclusions
The significant Ag85A-specific T cell responses and lack of difference between Sm-infected
and uninfected participants is encouraging for tuberculosis vaccine development. The impli-
cations of pre-existing Ag85A-specific IgG4 antibodies for protective immunity against
tuberculosis among those infected with Sm are not known. MVA85A was safe in this
population.
Trial registration
ClinicalTrials.gov NCT02178748
Author summary
There is an urgent global need for an improved TB vaccine strategy. Adolescents are an
important target population for a TB vaccine. In field settings where the need for a vaccine
is greatest, co-infection with other pathogens including malaria, HIV and helminths, may
interfere with the impact of such strategies. In this study, we used a model TB vaccine can-
didate based on a genetically engineered viral vector, and with an excellent safety profile,
to determine whether there was any immunological interference when this vaccine was
used in adolescents who were co-infected with S. mansoni. Our data shows comparable
immunogenicity in adolescents infected and uninfected with S. mansoni, suggesting that
co-infection with this helminth species may not have an adverse impact on candidate TB
vaccines of this type. The vaccine was safe and induced robust cellular responses in both
the infected and uninfected adolescents following immunisation. These findings are
important and encouraging for tuberculosis vaccine development.
Introduction
Helminth infection is widespread with over a billion people infected worldwide [1]. In 2014, at
least 258 million people required treatment for schistosomiasis, 90% of whom lived in Africa
[2]. In animal models, schistosomiasis impairs responses to immunisation against hepatitis B
[3], malaria [4], mycobacterial infection and BCG immunisation [5, 6]. In humans, the effects
are less clear. Helminth infections can modulate vaccine-induced responses against tetanus
[7], influenza [8], cholera [9], and Salmonella typhi [10]. T-helper (Th)1 responses are impor-
tant for protective immunity against intracellular bacteria and viruses, while helminths charac-
teristically induce Th2 [11] and immunoregulatory responses, both of which can down-
regulate Th1 pathways [8]. If concurrent helminth infection impairs vaccine-induced immu-
nity, policies for helminth treatment before, or at, the time of immunisation may be needed.
Tuberculosis (TB) remains a global health problem with very high mortality and morbidity.
In 2014, there were an estimated 9.6 million new cases and 1.5 million deaths from the disease
[12]. The only licensed TB vaccine, Bacille Calmette-Gue´rin (BCG), prevents severe disease in
childhood [13–15] but does not protect against pulmonary TB in many parts of the world.
Development of an effective vaccine is a key strategy for combating the epidemic.
Adolescents are an important target population for a TB vaccine [16, 17] because TB pres-
ents as the pulmonary (transmissible) form, in adolescents and young adults. However,
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adolescents harbour a high prevalence and intensity of helminth infection in countries where
helminths are endemic.
MVA85A, a recombinant Modified Vaccinia Ankara virus expressing the Mycobacterium
tuberculosis (Mtb) antigen 85A, is a clinically advanced TB vaccine candidate. It has been
administered to over 2400 human subjects and has an excellent safety profile. It is highly
immunogenic in BCG-primed UK adults [18], but only modestly immunogenic in BCG-vacci-
nated South African infants [19], and did not confer protection in either BCG-vaccinated
infants or HIV-infected adults [20]. Reasons for the reduced immunogenicity, and methods of
enhancing immunogenicity, are currently being evaluated [21]. Co-infection with helminths
may contribute to poor immunogenicity in high TB burden countries.
We here use MVA85A, a candidate TB vaccine with an excellent safety profile, as a model
TB vaccine candidate with which to evaluate the effect of S. mansoni (Sm) infection on the T
cell immunogenicity induced. Findings from this study may be important for all TB vaccine
development.
Materials and methods
Ethics statement
The study was approved by the Research Ethics Committee of the Uganda Virus Research
Institute, the Uganda National Council for Science and Technology, the Uganda National
Drug Authority, Oxford Tropical Research Ethics Committee, and London School of Hygiene
& Tropical Medicine Ethics Committee. Participants provided written informed assent and
their parents or guardians gave written informed consent.
Study design
This was a phase II open-label, non-randomised trial with two trial groups: Group 1 without
any current helminth infection detected and Group 2 with current Sm infection only. Labora-
tory staff performing immunological assays were blinded to helminth infection status.
The primary objective was to compare the T cell immunogenicity of MVA85A in adoles-
cents with and without Sm infection. Secondary objectives were to explore effects of Sm infec-
tion on other aspects of the immune response following MVA85A immunisation and to assess
the safety of MVA85A in BCG-vaccinated Ugandan adolescents.
Study setting
The study took place in five primary schools within schistosomiasis-endemic areas in Wakiso
District, Uganda, on the shores of Lake Victoria, between June 2014 and January 2015. Com-
munity leaders, district Ministry of Education and Health officials and school staff were con-
sulted and parent-teacher meetings held before the trial started to describe the trial, explain
procedures and answer questions.
Pre-screening
Pre-screening, by Kato Katz microscopy, was undertaken by the Vector Control Division
(VCD) of the Ministry of Health who hold the mandate to screen for helminths in Ugandan
schools. Children who had no helminths (candidates for Group 1) or Sm only (candidates for
Group 2), who were within the eligible age group and who had a BCG scar, were invited for
screening visits.
Schistosomiasis and TB vaccine response
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Recruitment and follow up
Assenting adolescents, with consent from a parent or guardian, were screened on the school
premises. A maximum of 60 days was allowed between screening and vaccination. Participants
provided blood for haematology and biochemistry, urine and three stool samples at screening,
and blood samples for evaluation of immune responses at screening, enrolment and 7, 28 and
56 days post-vaccination. Stool samples for Kato Katz for all participants were performed at
D28 and D56. Group 2 participants had an extra visit at D42 for anthelminthic treatment.
Exclusion and inclusion criteria
Participants were eligible for vaccination if aged 12 to 17 years, resident in the study area,
BCG-vaccinated (based on BCG scar or written documentation), healthy by history and physi-
cal examination. Exclusion criteria were clinical, radiological, or laboratory evidence of, or
previous treatment for, active or latent TB (including a positive ELISpot for ESAT6 or CFP10
at screening); sharing a residence with an individual on anti-TB treatment or with culture or
smear-positive pulmonary TB within the last year; positive serology for HIV (Murex Diasorin,
Italy and Vironostika, Biomerieux, France), hepatitis B or C (Innotest HCV Ab IV, Innoge-
netics, Belgium); positive rapid diagnostic test for malaria (SD-Bioline Inc, Korea); Mansonella
perstans infection (modified Knott’s method [22]); intestinal parasites other than Sm; preg-
nancy; history of anaphylaxis or allergy likely to be exacerbated by vaccine; haematological or
biochemical findings deemed clinically significant at screening; Sm infection intensity>2000
eggs per gram of stool (these individuals were treated immediately).
Definition of study groups
Three baseline stool samples were examined by the Kato Katz method [23, 24]. Urine was
examined for schistosome circulating cathodic antigen (CCA) by rapid test (ICT International,
Cape Town, South Africa). Participants were recruited to Group 1 (no helminths) if none of
these assays were positive. Participants were recruited to Group 2 (Sm infected) if at least one
stool sample was microscopy positive on Kato Katz examination for Sm, and none of the inves-
tigations were positive for any other helminths.
One stool sample per participant was also examined by PCR [25–28] for Sm, Strongyloides
stercoralis and Necator americanus (helminths prevalent in the area [29, 30]). Participants were
excluded from Group 1 if Sm positive and from both groups if S. strongyloides positive. The
protocol initially required exclusion from both groups if PCR positive for N. amercianus, how-
ever, this was amended when a high proportion of Sm positive individuals were found to be N.
americanus PCR positive (despite having three samples negative by microscopy).
Investigational medicinal product
MVA85A was produced under Good Manufacturing Practice conditions by IDT Biologika
GmbH, Dessau-Rosslau, Germany. It was stored at -80˚C in a locked, temperature-monitored
freezer at the Uganda Virus Research Institute-International AIDS Vaccine Initiative HIV
Vaccine Program pharmacy, Entebbe. On vaccination days, vaccine was transported from
pharmacy to field on dry ice.
Vaccination
All participants received 1x108 plaque forming units (PFU) MVA85A as a single intramuscular
injection in the deltoid region.
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Anti-helminthic treatment
All participants were treated for helminths with praziquantel (40mg/kg) and albendazole (400
mg) under observation by trial staff. Group 1 received a single dose on D56 (in accord with
annual mass treatment performed by VCD). Group 2 participants received two doses of prazi-
quantel, one on D28 (after samples were obtained) and one on D42, to optimise clearance of
infection. In this community, free diagnosis and treatment for Schistosomiasis is largely pro-
vided by the VCD, with whom we worked, so any treatment was done with the study team’s
knowledge.
Endpoints
The primary endpoint was T cell immunogenicity assessed by ex vivo Ag85A-specific inter-
feron gamma (IFN-γ) ELISpot response. Secondary endpoints were the profile of cytokine
responses assessed by multiplex Luminex assay of supernatant following six-day whole blood
stimulation, plasma antibody concentrations, and solicited and unsolicited local and systemic
adverse events.
Immunological assays
Ex vivo IFN-γ ELISpot assay. Antigen-specific IFN-γ secreting cells were detected by
ELISpot on fresh peripheral blood mononuclear cells (PBMC), using IFN-γ ELISpot kits
(Mabtech, Sweden) as previously described [18, 21, 31, 32]. Briefly, IFN-γ was assessed in
PBMC (0.3x106/well) in response to PPD-T (20μg/ml), ESAT-6 (10μg/ml), CFP-10 (10μg/ml)
and Ag85A (a single 66 peptide pool; 2μg/ml). Media only and SEB (10μg/ml) were used as
negative and positive controls. Plates were read using an ELISpot AID reader. Results were
obtained by subtracting mean background responses in unstimulated wells from mean
responses in stimulated wells and reported as spot-forming cells (SFC) per million PBMC.
Whole blood stimulation and multiplex Luminex assay
Whole blood assays were conducted as previously described [18, 31, 33]. Briefly, whole blood
diluted to a final concentration of 1:4 in RPMI supplemented with 10% Fetal Calf Serum
(R10) was stimulated with Ag85A (2μg/ml), PPD-T (10μg/ml), schistosome worm antigen
(SWA;10μg/ml, provided by Professor M Doenhoff, University of Nottingham, UK) and phy-
tohaemaggluttin (Sigma-Aldrich; 10μg/ml) or left unstimulated and incubated for 6 days in
5% carbon dioxide at 37˚C. Cytokine responses (IFN-γ, interleukin (IL)10, tumour necrosis
factor (TNF)α, granulocyte-monocyte stimulating factor (GMCSF), IL12P40, IL13, IL17A,
IL1A, IL2, IL5, inducible protein (IP)10, macrophage inflammatory protein-1-alpha (MIP1α),
IL6, IL1270, IL4, monocyte chemoattractant protein-3 (MCP3) and macrophage-derived che-
mokine (MDC)) in culture supernatants were assessed using a MILLIPLEX MAP Kit, (EMD
Millipore Corporation, Billerica, MA, USA). Detection antibody cocktail, streptavidin-phyco-
erythrin working concentrations, and the bead cocktail were diluted to allow three plates to be
run from each kit.
Antibody ELISA
ELISA assays were used to measure levels of total IgG, IgG1, IgG4 and IgE to Ag85A, SWA
and SEA using an established protocol modified to include responses to mycobacterial anti-
gens [34], detailed in the supplementary methods (S1 Methods).
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Parasite PCR assays
A portion of a stool sample from each participant was suspended in ethanol and stored at
-80˚C. Subsequently, DNA was extracted and samples were examined for Sm, S. stercoralis and
N. americanus DNA, as previously described [25].
Aliquots of EDTA-anticoagulated whole blood were stored at -80˚C. To investigate for low-
intensity Plasmodium falciparum infection (the common malaria species in this setting [35]
which could have been missed by the rapid diagnostic test) DNA was extracted from 500μl
whole blood then assessed using Real Time PCR as previously described [36] and detailed in
the supplementary methods (S1 Methods). A positive malaria PCR was not an exclusion crite-
rion for eligibility.
Adverse events
Solicited and unsolicited adverse events were collected using a diary card completed at home
by the participant from D0 to D6 and were assessed by the clinician at every clinic visit.
Statistical methods
The initial plan was to enrol 30 subjects in group 1 and 40–60 subjects in group 2. The sample
size was amended due to challenges with enrolment, to 12–24 subjects in each group. With
12–18 participants in each group, the study had 56–74% power to detect a 40% reduction in
geometric mean SFUs, and 82–94% power to detect a 50% reduction. The sample size calcula-
tion was based on previous ELISpot data from an adolescent trial [37] and assumed a mean
response on the log-scale for SFUs of 6.40 with a standard deviation of 0.59 corresponding to a
geometric mean of 600 SFUs on the back-transformed original scale. The initial plan was to
match participants in the two groups by age and gender, however, this was not possible and
these variables were therefore considered a priori as confounders.
The primary immunogenicity analysis was comparison of Ag85A ELISpot responses
between Sm infected (Group 2) and uninfected (Group 1) adolescents at peak response (D7).
Non-parametric analyses using the Mann Whitney U-test and multiple linear regression with
bootstrapped confidence intervals adjusting for age, gender, school and hookworm PCR
results were used. Area under the curve (AUC) analysis was done from D0 to D28.
Multiplex Luminex data were analysed using R (version 3.2.2). Unstimulated cytokine
responses were subtracted from antigen-stimulated results and negative values were assigned
0. Baseline responses were compared between the groups and change following vaccination
was evaluated. Cytokine responses were compared between Sm infected and Sm uninfected
individuals by fitting regression models which also contained terms for appropriate confound-
ers [38], age, gender and school. Mean (geometric mean) fold differences were calculated.
Principal component analysis was conducted on the standardised log AUC cytokine data. Bon-
ferroni corrections were used to account for multiple testing.
For antibody concentrations, comparisons were made between baseline levels and change
following vaccination.
Solicited and unsolicited adverse events overall and for each group were summarised by fre-
quency and severity.
Results
1068 pupils were pre-screened, and 174, who were within the target age group of 12–17 years,
were approached for screening. Sixty-seven were excluded before consenting, 35 because parents/
guardians declined to consent; 12 had no BCG scar; 10 left school during the initial processes; five
Schistosomiasis and TB vaccine response
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had no adult or responsible legal guardian accessible for consenting; three had recently been
treated for schistosomiasis; one volunteered known HIV-positive status and one was found to be
under age at screening (11 years) despite having reported being 12 years at pre-screening. 107 sub-
jects consented, assented and were screened for eligibility of whom 36 were enrolled (Fig 1).
Eighteen subjects had Sm infection only and were enrolled into Group 2, 18 had no hel-
minth infection detected and were enrolled into group 1 (3 of these subsequently had Sm
detected on PCR and were excluded from all further analysis). Participants in Group 1 and 2
differed in age, school and N. americanus PCR status (Table 1).
Effect of S. mansoni on vaccine immunogenicity
The peak D7 Ag85A IFNγ ELISpot response was compared between groups. Two participants
from group 1 and four from group 2 with missing data were excluded from the analysis.
Median Ag85A SFC/ 1x106 PBMC were not significantly different (Mann-Whitney p = 0.65).
Regression and AUC analysis of the Ag85A ELISpot response (D0 to D28) adjusting for age,
gender, school and stool PCR for N. americanus showed no evidence of an association between
Sm infection and MVA85A induced IFNγ response (see Table 2 and Fig 2).
D7 ELISpot and AUC analysis (D0—D28) for purified protein derivative (PPD) responses
showed no significant difference between the two groups (S1 Table). ESAT and CFP 10
responses remained negative at all time points (S1 Fig).
Ag85A antibody levels were not significantly different in the two groups with the exception
of IgG4, which was significantly higher in the Sm infected group at baseline and at all time
points post-vaccination (Fig 3); this difference remained significant after correcting for multi-
ple testing using Bonferroni correction (p = 0.012). Ag85A-specific antibodies were present at
baseline and showed no significant change post-vaccination. Our assay did not detect much
Ag85A specific IgE in the study participants.
SWA-specific IgG antibodies and sub-classes were significantly higher (p values for
IgG = 0.0060, IgG1 = 0.0136 and IgG4 = 0.0004) in the Sm infected group (Fig 4). SWA-spe-
cific IgE levels were low in both groups, and no statistically significant differences were seen
between the groups (Fig 4). SWA-specific antibody levels tended to increase at day 56 in the
Sm infected group (after praziquantel treatment). Exploring the observed elevated levels of
Ag85A-specific IgG4, we found no correlation between SWA or SEA-specific IgG4 and
Ag85A-specific IgG4 among Sm-infected participants.
Analysis of the multiplex Luminex assays following six-day stimulation and culture for
Ag85A and PPD stimulation showed no significant difference in pre-immunisation responses
for any cytokine, and all cytokines showed an enhanced response post-vaccination in both
groups, with the exception of IL2, for which measured levels were very low. There was no signif-
icant difference post-vaccination in levels of any individual cytokine. Regression analysis (sup-
plementary S3 and S4 Tables) of AUC accounting for age, gender and school as confounders
suggested a higher response to Ag85A and PPD among Sm infected compared to uninfected
participants for all cytokines except IL12P40 (to Ag85A) and IL2 (to both Ag85A and PPD).
There was no significant difference in geometric means following stimulation with Ag85A and
PPD for any of the cytokines (except for IL1A to PPD, p value = 0.017) between uninfected and
infected when adjusted for multiple testing using Bonferroni correction (S3 and S4 Tables).
Safety results
Safety results were considered for all 36 subjects who received the vaccine despite the fact that
three subjects initially allocated to Group 1 were found to have Sm on PCR and therefore
excluded from the immunogenicity analysis (Table 3 and S2 Table).
Schistosomiasis and TB vaccine response
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Fig 1. CONSORT flow diagram showing volunteer recruitment and follow up. Abbreviations: CCA, schistosome circulating cathodic antigen;
KK, Kato Katz; RDT, rapid diagnostic test; Sm, Schistosoma mansoni.
https://doi.org/10.1371/journal.pntd.0005440.g001
Schistosomiasis and TB vaccine response
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No serious adverse events were reported in this trial. Using data collected from the diary
cards and at clinic visits on days 0, 7, 28 and 56, all 36 children reported at least one adverse
event. 34 (94%) of 36 children vaccinated experienced at least one local adverse event and 6
(17%) experienced at least one systemic event. There was no difference in adverse events
between the two groups. All adverse events had resolved by day 56.
Local warmth (94%) and pain (92%) at the injection site were the most commonly reported
of the solicited local adverse events by subjects in both groups, while headache (69%) was the
most commonly reported of the solicited systemic adverse events in the diary card. The AE
profile was not different in those excluded from the immunogenicity analysis.
Table 1. Baseline characteristics of eligible subjects by group.
Characteristics Level Group 1 Group 2
No Helminths Sm Only
(n = 18) (n = 18)
n (%) n (%)
Age group (years) 11–12 6 (33) 8 (44)
13–14 11 (61) 7 (39)
16–17 1(6) 3 (17)
Gender Male 10 (56) 10 (56)
Female 8 (44) 8 (44)
School Busabala P/S 0 (0) 6 (33)
Officers’ children P/S 1 (6) 1 (6)
Kigo-Lunnya P/S 5 (28) 2 (11)
Bulega P/S 6 (33) 9 (50)
Bugiri P/S 6 (33) 0 (0)
Mother’s education None 1 (6) 1 (6)
Primary 10 (56) 13 (72)
Secondary or higher 7 (39) 3 (17)
Unknown 0 (0) 1 (6)
Bathe in lake water No 12 (67) 4 (22)
Yes 6 (33) 14 (78)
Stool PCR for hookworm Positive 3 (17) 2 (11)
Negative 15 (83)a 16 (89)
Malaria PCR Positive 4 (22)b 1 (6)
Negative 14 (78)c 17 (94)
Intensity of Sm infection Uninfected 18 (100) 0 (0)
Light (1–99 epg) 0 (0) 13 (72)
Moderate (100–399 epg) 0 (0) 1 (6)
Heavy (400–1999d epg) 0 (0) 4 (22)
Status for primary Excluded–due to helminths 3 (17) 0 (0)
immunogenicity analysis of Day 7 ELISpot missing 2 (11) 4 (22)
Ag85A Included 13 (72) 14 (78)
Abbreviations: Sm, Schistosoma mansoni; P/S, primary school; PCR, polymerase chain reaction; epg, eggs per gram of stool
a. Three excluded from immunogenicity analysis due to misallocation
b. Two excluded from immunogenicity analysis due to misallocation
c. One excluded from immunogenicity analysis due to misallocation
d. Individuals with egg counts 2000 epg were excluded and treated immediately.
https://doi.org/10.1371/journal.pntd.0005440.t001
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259 graded adverse events were recorded (See S2 Table). 192 (72%) of the adverse events
were mild. Two severe adverse events occurred and were pain at vaccination site and itching at
vaccination site, both observed in participants in the no helminth group.
Discussion
MVA85A induced a robust cellular response, with no difference in cellular immunogenicity
between adolescents with and without current Sm infection. MVA85A did not boost the base-
line Ag85-specific antibody response (as expected [18]). Levels of Ag85A specific IgG4 anti-
body were elevated among the Sm infected participants at baseline and at all subsequent time
points. The safety profile was consistent with other published data on this vaccine from Afri-
can populations [37, 39].
Table 2. Regression Analysis of Ag85A IFN-γ response as measured by ELISPOT on day 7 and Area Under the Curve analysis for days 0 to 28.
Factor Level Estimate (Bootstrap 95% P-value
C.I)
Ag85A at day 7
Constant 1272.3 (-2066.5; 4611.0) -
Age Per one year -76.4 (-303.9; 151.2) 0.51
increase
Sex Male 0 (Ref) 0.41
Female 232.4 (-318.8; 783.1)
School Busabala 0 (Ref) 0.12
Officers’ children -225.6 (-1432.9; 981.8)
Kigo-Lunya 35.2 (-1055.7; 1126.1)
Bulega 471.9 (-346.0; 1289.7)
Bugiri 563.3 (-750.2; 1876.9)
Hookworm stool Negative 0 (Ref) 0.67
PCR Positive 216.0 (-735.8; 1167.8)
Helminth Group No helminth 0 (Ref) 0.65
S. mansoni only 185.1 (-607.3; 977.4)
AUC for Ag85A (day 0-day 28)
Constant 14 692 (-90 254; 119 639) -
Age Per one year -821 (-8 565; 6 923) 0.84
increase
Sex Male 0 (Ref) 0.68
Female 3 018 (-11 301; 17 336)
School Busabala 0 (Ref) 0.32
Officers’ children 43 (-27 250; 27 336)
Kigo-Lunya 4 839 (-19 193; 28 872)
Bulega 7 219 (-12 637; 27 075)
Bugiri 20 711 (-6 649; 48 071)
Hookworm stool Negative 0 (Ref) 0.92
PCR Positive -1 118 (-24 189; 21 954)
Helminth Group No helminth 0 (Ref) 0.56
S. mansoni only 5 673 (-13 511; 24 856)
Abbreviations: Ag85A, Antigen 85A; IFN-γ, interferon gamma; C.I., confidence interval; PCR, polymerase chain reaction; Sm, Schistosoma mansoni; Ref,
reference; AUC, Area under the curve
https://doi.org/10.1371/journal.pntd.0005440.t002
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Fig 2. Ex-vivo interferon gamma responses to antigen 85A and purified protein derivative at each time point.
Boxes in white represent uninfected children, grey represent Sm infected children. Boxes and whiskers show
interquartile ranges and minimum and maximum values with horizontal lines representing medians. Participants in the
Schistosomiasis and TB vaccine response
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Sm infected group were treated with praziquantel and albendazole twice between day 28 and day 56. Abbreviations:
IFN-γ, interferon gamma; Ag85A, antigen 85A; PPD, purified protein derivative; Sm, Schistosoma mansoni.
https://doi.org/10.1371/journal.pntd.0005440.g002
Fig 3. Antibody responses to Mycobacterium tuberculosis antigen 85A. Boxes in white represent uninfected children, grey represent
Sm infected children. Boxes and whiskers show interquartile ranges and minimum and maximum values with horizontal lines representing
medians. Participants in the Sm infected group were treated with praziquantel and albendazole twice between day 28 and day 56.
Abbreviations: Ag85A, antigen 85A; Sm, Schistosoma mansoni
https://doi.org/10.1371/journal.pntd.0005440.g003
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The peak (D7) Ag85A ELISpot response of>500 SFC/million PBMC, was comparable to,
or higher than, responses previously observed among adolescents and adults in the Cape
region of South Africa [37, 39], where lifetime exposure to schistosomiasis and other tropical
Fig 4. Antibody responses to schistosome worm antigen. Boxes in white represent uninfected children, grey represent Sm infected
children. Boxes and whiskers show interquartile ranges and minimum and maximum values with horizontal lines representing medians.
Participants in the Sm infected group were treated with praziquantel and albendazole twice between day 28 and day 56. P values for
statistically significant differences in SWA-specific antibody responses between the groups were 0.0060 for IgG, 0.0136 for IgG1 and 0.0004
for IgG4. Abbreviations: SWA, schistosome worm antigen; Sm, Schistosoma mansoni
https://doi.org/10.1371/journal.pntd.0005440.g004
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parasitic infections is likely to be lower than in tropical Africa [40]. Current exposure to Sm
among Ugandan adolescents did not impair the cellular immunogenicity of MVA85A. This is
important given the poor efficacy of BCG in tropical latitudes [41]. One potential advantage
for booster TB vaccines may be prior exposure to environmental mycobacteria: besides BCG,
the Ugandan participants would have been extensively exposed to environmental mycobacte-
ria [42], as evidenced by anti-mycobacterial antibody levels prior to MVA85A vaccination
[18]. A point for caution is that selection for prior BCG based largely on BCG scar (as most
had no records available) may have biased recruitment to individuals who received a more
immunogenic formulation of BCG, or who were predisposed to stronger anti-mycobacterial
responses, since scarring varies between BCG strains and only about 60% of infants scar in
response to strains commonly used in Uganda [43].
Our initial focus was on Th1 cytokines as measured by ex-vivo ELISpot and Luminex, as
there is clear evidence for a role for Th1 cytokines in protective immunity against Mycobacte-
rium tuberculosis. Given the increased interest in a role of humoral immunity and B cells in
protective immunity against mycobacteria, we also investigated the humoral response as mea-
sured by IgG to the Ag85A insert. Further measures of immunogenicity such as mycobacterial
growth inhibition assays and other T cell functions may be considered as part of future work
on stored samples from this trial. There is as yet no clearly defined immunological correlate of
protection with which to measure candidate vaccine immunogenicity. However, the recent
paper by Fletcher et al [44] indicated that pre-MVA85A-immunisation BCG-specific ELIspot
responses and post MVA85A antibody (specific for antigen 85) were protective. We did not
perform the former but did measure the latter and observed no effect.
Table 3. Number and percentage of subjects reporting each adverse event
Group 1 (No Helminths)
(n = 18)a
Group 2 (Sm only)
(n = 18)
Adverse events Day Diary Day Day Day Day Diary Day Day Day
0 card 7 28 56 0 Card 7 28 56
Solicited local Local pain 7(39) 15(83) 2(11) 0(0) 0(0) 3(17) 18(100) 1(6) 0(0) 0(0)
AEs
Local warmth 17(94) 11(61) 1(6) 0(0) 0(0) 17(94) 9(50) 0(0) 0(0) 0(0)
Local swelling 1(6) 0(0) 2(11) 0(0) 0(0) 2(11) 0(0) 2(11) 0(0) 0(0)
Local itching 2(11) 8(44) 0(0) 0(0) 0(0) 1(6) 7(39) 0(0) 0(0) 0(0)
Scaling 0(0) 1(6) 3(17) 0(0) 0(0) 0(0) 2(11) 2(11) 1(6) 0(0)
Unsolicited AEs 11(61) 9(50)
Solicited Documented 2(11) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)
systemic AEs fever
Symptoms of 0(0) 11(61) 0(0) 0(0) 0(0) 0(0) 11(61) 0(0) 0(0) 0(0)
feverishness
Malaise 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)
Arthralgia 0(0) 8(44) 2(11) 0(0) 0(0) 0(0) 6(33) 0(0) 0(0) 0(0)
Headache 2(11) 13(72) 0(0) 2(11) 0(0) 0(0) 12(67) 0(0) 0(0) 0(0)
Myalgia 0(0) 5(28) 2(11) 0(0) 0(0) 0(0) 5(28) 0(0) 0(0) 0(0)
Fatigue 1(6) 10(56) 1(6) 0(0) 0(0) 0(0) 7(39) 1(6) 0(0) 0(0)
Nausea 1(6) 5(28) 0(0) 0(0) 0(0) 0(0) 4(22) 0(0) 0(0) 0(0)
Abbreviations: Sm, Schistosoma mansoni; AEs, Adverse events
a. Includes three participants subsequently excluded from the immunogenicity analysis due to misallocation
https://doi.org/10.1371/journal.pntd.0005440.t003
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Recruitment to this study was challenging and the final sample size had power only to
detect a large effect of current Sm infection on vaccine immunogenicity. However, there is no
suggestion in the data that Sm was associated with a reduced or biased response to immunisa-
tion. If anything, cellular responses to MVA85A were slightly stronger, and increased further
following treatment with praziquantel, in the Sm infected group. This was surprising given
prior results in animal models of schistosomiasis and BCG immunisation and infection [5, 6].
Our findings in the human population may relate, again, to the impact of prior mycobacterial
exposure, to intensity of Sm infection (low in most of our subjects) and to the characteristics
of MVA85A (a viral vector vaccine which enters host cells but does not replicate [18]) as
opposed to BCG (an attenuated mycobacterial vaccine which replicates in the host).
Lack of bias in the profile of cytokine response following MVA85A was also surprising,
given evidence from earlier studies of Th2 bias following tetanus immunisation among indi-
viduals with Sm infection [7], and more particularly given evidence of bias in the antibody
response to Ag85A (to IgG4) prior to MVA85A administration.
The groups in this study were defined by detection of current Sm infection. It is possible
that prior helminth exposure might influence vaccine responses (rendering current status less
relevant). Recent helminthic disease acquisition in the Sm negative group during follow up,
detectable by Kato Katz, was ruled out using the follow up samples collected. It is plausible that
previous exposure to helminths in the Sm negative group (which we could not measure in this
study) may be responsible for the lack of difference, but the differences in Sm-specific antibody
levels make this unlikely. For the Sm positive group, we expect that infections were chronic–as
we have previously reported among adults in related fishing communities [45]. The finding
that schistosome-specific IgG levels were significantly higher in the Sm infected group suggests
that these individuals differed in prior, as well as current, Sm exposure. Sm-specific IgE
increases gradually among exposed populations. Low levels in these adolescents (Sm infected
or otherwise) is in keeping with this pattern [46–49].
This was an observational study, susceptible to unmeasured confounding. We attempted
to exclude confounding by parasitic co-infections by enrolling participants in whom no
other parasites that are common in this setting could be detected. This proved challenging
for sub-microscopic hookworm and malaria infection, but adjusting for hookworm PCR
status and sub-microscopic malaria (measured by malaria PCR) made no difference to the
results.
It may not be possible to extrapolate these findings to other vaccines and other species of
helminth. There is substantial evidence of variability between populations in vaccine immuno-
genicity: notably, impaired responses to yellow fever vaccine were observed in Uganda, com-
pared to Switzerland, in a study that found reduced vaccine virus replication and neutralising
antibody production and persistence, in the context of elevated innate and adaptive immune
response activation, among Ugandan volunteers [50]. There is evidence, for other vaccines, of
differences (such as Th2 bias) in the response between people with and without schistosomia-
sis [7, 10], and of modulation of vaccine responses by other helminth species [8, 9]. Key factors
in helminth-vaccine interactions are likely to include vaccine characteristics (live, replicating,
protein or toxoid), prior exposure to environmental organisms or pathogens homologous to
the vaccine, and the nature of the desired response (cellular or antibody).
We conclude that current Sm infection did not interfere with the cellular immunogenicity
of MVA85A in our study population. These findings are important and encouraging for the
development of TB vaccines in general, and support the further development of booster TB
vaccines for populations in tropical countries. MVA85A was safe in this population of African
adolescents.
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